

Hilltop Bio Intra-Articular Strydaflex Pilot Safety Study

Hilltop Biosciences has formulated a new lyophilized equine sourced product containing cytokines, growth factors, and exosomes for intra-articular use in horses with mild to moderate osteoarthritis, Strydaflex. As a first step in determining the effects of any potential new product, assessing the safety of the formulation is of utmost importance. To examine the effects of intra-articular Strydaflex, a pilot safety study was performed. The primary outcome objective was to determine the safety of the product when injected intra-articularly, and secondarily to assess the effects on clinical lameness.

Discussion:

The primary objective of this study was to assess the safety of intra-articular lyophilized Strydaflex in 25 horses with synovitis and/or lameness. The secondary objective was to assess the clinical effect on the associated lameness.

There were no systemic indications of adverse events following intra-articular Strydaflex and no injection site reactions noted. Six horses (6/25, 24%) demonstrated a one grade increase in heat in the affected joint within 48 hours of injection, all resolved without treatment within the following two time points, and all 25 horses had a heat score of zero by study end. One horse (1/25, 4%) demonstrated an increase of one grade on the AAEP lameness scale at one intermediate time point (24-hours post injection) that returned to baseline at the 48-hour timepoint without treatment. By the end of the study this horse had improved one degree over baseline lameness grade.

Twenty of the horses entered the study with clinical lameness. All twenty horses demonstrated at least a one grade improvement in lameness following intra-articular Strydaflex. Fourteen of the horses (14/20, 70%) ended the study as a grade zero or grade one clinical lameness.

While a larger randomized, controlled, blinded study is needed to make more definitive claims, these results appear to demonstrate clinical benefits of intra-articular lyophilized Strydaflex for managing clinical synovitis and lameness in horses with a lack of significant adverse events.

For more information:

Contact your local Hilltop Bio representative

Hilltop Bio Office at 617-237-0636

Email info@hilltopbio.com